Immune checkpoint inhibitors (ICIs) have recently transformed the therapeutic landscape of advanced NSCLC, with agents such as sintilimab demonstrating meaningful efficacy by blocking the PD-1/PD-L1 axis, thereby reversing tumor-induced immune evasion and restoring T-cell–mediated antitumour immunity (5). Here, CD274 is linked to neoplasm.